Medical News

RSS

Insurers expand business overseas

The Wall Street Journal: "Cigna Corp. is expanding overseas, leading a push by health insurers to find growth amid uncertainties at home. Next month, the Philadelphia-based firm will launch an insurance policy in Spain that it says is the first of its kind to be sold by U.S. insurers. The new plan is sold directly to local individuals, as opposed to employer-sponsored or supplemental policies offered by Cigna in 26 other countries.

15 Sep 2010

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Elsevier today announces that it has significantly increased its service offering to pharmaceutical R&D professionals with the launch of a new Pharmacokinetics Module of PharmaPendium-, the online resource for authoritative drug development data.

15 Sep 2010

Helix BioPharma receives authorization to list shares on NYSE Amex stock exchange

Helix BioPharma Corp. today announced that it has been authorized to list its shares of common stock on the NYSE Amex stock exchange. The Company expects that shares of its common stock will begin trading on the NYSE Amex on September 15, 2010, under the trading symbol "HBP."

15 Sep 2010

Key health law provisions begin Sept. 23

In her latest Kaiser Health News consumer column, Michelle Andrews writes: "The elimination of lifetime caps on benefits is one of several provisions that will begin to take effect Sept. 23, six months after enactment of the law.

15 Sep 2010

School leavers at risk for obesity: Study

In a large scale national study it has been found that the period of leaving school is a high risk one for obesity and weight gain. The study authors say that obesity rates double in the short transition from adolescence to adulthood in over 1,500 young people included in the study.

15 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

Volcano Corporation announces pricing of convertible senior notes due 2015

Volcano Corporation today announced the pricing of its offering of $100 million aggregate principal amount of 2.875 percent convertible senior notes due September 1, 2015 registered under the Securities Act of 1933, as amended. Prior to June 1, 2015, the notes will be convertible only upon certain circumstances.

15 Sep 2010

Early alcohol, tobacco exposure may delay puberty in girls: Study

The list of possible health effects from an early introduction to alcohol and tobacco use has just gotten longer. A new study suggests that early drinking and smoking might delay onset of puberty in girls.

15 Sep 2010

Opinions: Global nursing; U.S. funding of Global Fund; Global demands for water; Food security

"Almost every nation, regardless of its wealth and resources, faces a continuing shortage of nurses and an acute lack of nursing faculty available to educate more nurses. This dearth of practicing nurses and nurse educators is particularly critical in countries like Haiti and other developing high-risk, low-resourced nations," Martha Hill, dean of Johns Hopkins School of Nursing, writes in a Baltimore Sun opinion piece encouraging the expansion of global nursing.

15 Sep 2010

Kings Cross drug injection center to become permanent fixture

After running for quite some time amidst intense debates, the New South Wales Government has announced plans to make the medically-supervised drug injecting centre at Kings Cross a permanent fixture. This unit has been functioning since 2001 and was still looking for permanency. A latest review of this trial center showed that it has successfully managed more than 3,000 overdoses and helped 12,000 drug users.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Researchers develop new blood test to predict prostate cancer risk

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.

15 Sep 2010

Today's Opinions: Medicare fixes, health care lawsuits, reporting repeals

And in this political climate, the $210 billion price tag [to fix the physician payment system] will probably prevent a permanent solution this year. However, a longer term, interim fix and a primary care payment differential would be steps in the right direction (Dennis Mayeaux and Lori Parham, 9/13).

15 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

AMS receives favorable ruling in Davenport infringement lawsuit

American Medical Systems Holdings, Inc., a leading provider of world-class devices and therapies for male and female pelvic health, announced today that the company is pleased with yesterday's U.S. Court of Appeals for the Federal Circuit's ruling that reversed a summary judgment and finding for Biolitec, Inc.

15 Sep 2010

Health on the Hill – September 13, 2010

Kaiser Health News staff writer Mary Agnes Carey talks with Politico's Jennifer Haberkorn and KFF's Jackie Judd about recent events in Washington, including Senate consideration of amendments to a package of small business tax breaks that would repeal a provision of the health care law that requires businesses to submit a 1099 form to the Internal Revenue Service for yearly purchases of $600 or more from a vendor.

15 Sep 2010

Researchers unveil watercress compound can block pathway for cancer development

The research, unveiled at a press conference today (14 September 2010), shows that the watercress compound is able to interfere with the function of a protein which plays a critical role in cancer development.

15 Sep 2010

Arizona State University receives grant to protect warfighters from infectious diseases

Scientists at the Biodesign Institute at Arizona State University have received a 2-year, $5.3 million grant from the Defense Advanced Research Projects Agency (DARPA) to protect warfighters in the event of exposure to infectious diseases during deployment.

15 Sep 2010

Scientists discover study of calcium deposits helps effective breast cancer diagnosis

SCIENTISTS have discovered for the first time that studying calcium deposits in the breast, often detected through screening, could help doctors diagnose breast cancer more effectively.The study, published in the British Journal of Cancer today (Wednesday), examined the relationship between the composition of these deposits found in breast tissue and the malignancy of a tumour.

15 Sep 2010

Medical News

Insurers expand business overseas

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Helix BioPharma receives authorization to list shares on NYSE Amex stock exchange

Key health law provisions begin Sept. 23

School leavers at risk for obesity: Study

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Volcano Corporation announces pricing of convertible senior notes due 2015

Early alcohol, tobacco exposure may delay puberty in girls: Study

Opinions: Global nursing; U.S. funding of Global Fund; Global demands for water; Food security

Kings Cross drug injection center to become permanent fixture

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

FDA approves Krystexxa drug to treat gout

Researchers develop new blood test to predict prostate cancer risk

Today's Opinions: Medicare fixes, health care lawsuits, reporting repeals

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

AMS receives favorable ruling in Davenport infringement lawsuit

Health on the Hill – September 13, 2010

Researchers unveil watercress compound can block pathway for cancer development

Arizona State University receives grant to protect warfighters from infectious diseases

Scientists discover study of calcium deposits helps effective breast cancer diagnosis

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News